Skip to main content

Table 2 Predictors of occurrence of relapse in the first year of treatment

From: Clinical baseline factors predict response to natalizumab: their usefulness in patient selection

 

Univariate analysis

Multivariate analysis

 

OR

CI

P

OR

CI

P

Sex (female vs male)

2.31

0.57–9.32

0.24

-

-

-

Age

1.00

0.94–1.07

0.88

-

-

-

Disease duration

1.01

0.92–1.11

0.81

-

-

-

ARR in the pre-treatment year

0.98

0.63–1.54

0.93

-

-

-

EDSS gain the pre-treatment year

1.53

0.89–2.62

0.12

-

-

-

EDSS at baseline

1.25

0.90–1.75

0.18

-

-

-

EDSS at baseline, categorized

  

0.62

-

-

-

   3.0 to 3.5 compared to < = 2.5

0.08

0.18–6.44

0.93

-

-

-

   4.0 to 5.5 compared to < = 2.5

1.58

0.29–8.61

0.6

-

-

-

   6 and above compared to < = 2.5

2.60

0.52–13.04

0.24

-

-

-

High pre-treatment disease activity

4.12

1.05–16.23

0.04

4.12

1.05–16.23

0.04

  1. OR: odds ratio. CI = 95% Confidence Interval.
  2. Univariate and multivariate logistic regression analysis.